We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Overdue process.
- Abstract
The article focuses on the impact of the suspension of Great Britain-based influenza vaccine manufacturer Chiron Corp. on healthcare agencies. The regulators are concerned with the problem of determining the types of test required to demonstrate that a brand protein and its generic copy are comparable in terms of protein purity, sequence, structure, species specificity, pharmacological and immunological effects. It is right that the biotech industry retains intellectual property protection and market exclusivity in return for investment in R&D. But attempts to thwart generics manufacturers on the basis of nebulous safety concerns more than smacks of protectionism.
- Subjects
UNITED Kingdom; CHIRON Corp.; INFLUENZA vaccines; BIOTECHNOLOGY industries; MEDICAL care; AMINO acid sequence
- Publication
Nature Biotechnology, 2004, Vol 22, Issue 11, p1329
- ISSN
1087-0156
- Publication type
Editorial
- DOI
10.1038/nbt1104-1329